Your browser doesn't support javascript.
loading
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.
Larocca, Alessandra; Leleu, Xavier; Touzeau, Cyrille; Bladé, Joan; Paner, Agne; Mateos, María-Victoria; Cavo, Michele; Maisel, Christopher; Alegre, Adrían; Oriol, Albert; Raptis, Anastasios; Rodriguez-Otero, Paula; Mazumder, Amitabha; Laubach, Jacob; Nadeem, Omar; Sandberg, Anna; Orre, Marie; Torrång, Anna; Bakker, Nicolaas A; Richardson, Paul G.
Afiliación
  • Larocca A; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero - Universitaria Città della Salute e della Scienza, Turin, Italy.
  • Leleu X; CHU de Poitiers, Poitiers, France.
  • Touzeau C; Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université d'Angers, Université de Nantes, Nantes, France.
  • Bladé J; Site de Recherche Intégrée sur le Cancer (SIRIC), Imaging and Longitudinal Investigations to Ameliorate Decision-making (ILIAD), Nantes, France.
  • Paner A; Service d'Hématologie Clinique, Centre Hospitalier Universitaire, Place Alexis Ricordeau, Nantes, France.
  • Mateos MV; Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain.
  • Cavo M; Rush University Medical Center, Chicago, IL, USA.
  • Maisel C; Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca, Spain.
  • Alegre A; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
  • Oriol A; Baylor Scott & White Charles A. Sammons Cancer Center, Dallas, TX, USA.
  • Raptis A; Hospital Universitario La Princesa and Hospital Universitario Quironsalud, Madrid, Spain.
  • Rodriguez-Otero P; Institut Català d'Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol, Badalona, Spain.
  • Mazumder A; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Laubach J; Clínica Universidad de Navarra, Pamplona, Spain.
  • Nadeem O; The Oncology Institute of Hope and Innovation, Glendale, CA, USA.
  • Sandberg A; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Orre M; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Torrång A; Oncopeptides AB, Stockholm, Sweden.
  • Bakker NA; Oncopeptides AB, Stockholm, Sweden.
  • Richardson PG; SDS Life Science, Danderyd, Sweden.
Br J Haematol ; 196(3): 639-648, 2022 02.
Article en En | MEDLINE | ID: mdl-34671975
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiple Tipo de estudio: Diagnostic_studies / Etiology_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Año: 2022 Tipo del documento: Article País de afiliación: Italia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiple Tipo de estudio: Diagnostic_studies / Etiology_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Año: 2022 Tipo del documento: Article País de afiliación: Italia